Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic has filed its Q1 FY26 (June 2025) investor presentation ahead of the August 11 earnings call. Total revenue grew 18.8% year-on-year to ₹735 million, driven by a 26% jump in tests performed to 1.92 million and 0.34 million patients served. EBITDA rose 13.5% to ₹247 million, with margin improving to 34% from 30.7% in Q4 FY25, and profit after tax climbed 19.7% to ₹92 million (EPS of ₹1.80). The company completed a 63% acquisition of Fetomat Wellness (fertility/pregnancy care) in April 2025 and launched a new 'Suraksha Genomics' vertical in July 2025, with ₹460 million in incremental investment planned over the next 24 months. The network now spans 9 labs, 58 diagnostic centres, and 170 collection centres, with 95% of revenue coming from West Bengal and expansion plans targeting Eastern and North-Eastern India.
Positive near-term: strong revenue and PAT growth with margin recovery from the prior quarter. New growth levers through Fetomat integration and the Genomics vertical could support multi-year revenue diversification beyond the West Bengal-heavy base, though execution and capex risks remain.